Yousif Capital Management LLC Sells 10,541 Shares of Johnson & Johnson $JNJ

Yousif Capital Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 3.2% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 320,149 shares of the company’s stock after selling 10,541 shares during the period. Johnson & Johnson makes up 0.6% of Yousif Capital Management LLC’s portfolio, making the stock its 15th biggest holding. Yousif Capital Management LLC’s holdings in Johnson & Johnson were worth $59,362,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Clark Asset Management LLC grew its stake in Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after buying an additional 3,025 shares in the last quarter. Treasurer of the State of North Carolina lifted its holdings in shares of Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after acquiring an additional 94,957 shares during the last quarter. Avanza Fonder AB grew its position in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares in the last quarter. Talbot Financial LLC increased its stake in Johnson & Johnson by 4.6% in the third quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock valued at $25,667,000 after acquiring an additional 6,143 shares during the last quarter. Finally, Winnow Wealth LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $295,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.1%

Shares of Johnson & Johnson stock opened at $208.01 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $215.18. The company’s 50 day moving average price is $199.06 and its 200-day moving average price is $180.31. The stock has a market capitalization of $501.14 billion, a price-to-earnings ratio of 20.08, a P/E/G ratio of 2.23 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Bank of America lifted their price target on shares of Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Stifel Nicolaus upped their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Finally, Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Four analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $210.25.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.